Results 21 to 30 of about 204,987 (288)

Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas

iScience, 2023
Summary: Evidence is mounting for cross-resistance between immune checkpoint and targeted kinase inhibitor therapies in cutaneous melanoma patients. Since the loss of the transcription factor, SOX10, causes tolerance to MAPK pathway inhibitors, we used ...
Timothy J. Purwin, Signe Caksa, Ahmet Sacan, Claudia Capparelli, Andrew E. Aplin   +4 more
doaj   +1 more source

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

Experimental Hematology & Oncology, 2020
This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production ...
Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen, Tue Wenzel Kragstrup   +3 more
doaj   +1 more source

The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology [PDF]

, 2019
Functional, tumor-specific CD8+ cytotoxic T lymphocytes drive the adaptive immune response to cancer. Thus, induction of their activity is the ultimate aim of all immunotherapies.
Dey, Mahua, Fetcko, Kaleigh, Henriquez, Mario, Huff, Wei X., Kwon, Jae Hyun   +4 more
core   +1 more source

Revving up dendritic cells while braking PD-L1 to jump-start the cancer-immunity cycle motor [PDF]

, 2016
Although it is successful for some, most melanoma patients are refractory to T cell checkpoint inhibition. In this issue of Immunity, Merad and colleagues (2016) describe a dendritic-cell-based strategy to heighten the efficacy of therapeutic anti-PD-L1 ...
Coffelt, Seth B., de Visser, Karin E.
core   +1 more source

Chronic immune checkpoint inhibitor pneumonitis

Journal for ImmunoTherapy of Cancer, 2020
Background Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related adverse event (irAE) from antiprogrammed death 1/programmed death ligand 1 immunotherapy. Most cases of ICI pneumonitis improve or resolve with 4–6 weeks
Julie R Brahmer, Patrick M Forde, Evan J Lipson, Jarushka Naidoo, Joanne Riemer, Daphne Wang, Janis M Taube, Cheng Ting Lin, Peter B Illei, Tricia R Cottrell, Lonny B Yarmus, K Ranh Voong, David Feller-Kopman, Hans Lee, Sonye K Danoff, Franco R D'Alessio, Karthik Suresh   +16 more
doaj   +1 more source

SnapShot: Immune Checkpoint Inhibitors

Cancer Cell, 2017
Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance).
Abril-Rodriguez, Gabriel, Ribas, Antoni
openaire   +4 more sources

Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration [PDF]

, 2020
Background Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related to the
Maestro, Alessandra, Marcuzzi, Annalisa, Maximova, Natalia, Zanon, Davide   +3 more
core   +1 more source

Targeting ATM pathway for therapeutic intervention in cancer [PDF]

, 2012
The Ataxia Telangiectasia Mutated gene encodes the ATM protein, a key element in the DNA damage response (DDR) signalling pathway responsible for maintaining genomic integrity within the cell.
Chakarov, Stoyan, Khalil, Hilal S., Lane, David P., Tummala, Hemanth, Zhelev, Nikolai   +4 more
core   +3 more sources

Immune Checkpoint Inhibitor-Associated Myocarditis

JACC: Case Reports, 2020
Immune checkpoint inhibitors (ICIs) can induce immunity-related adverse events. We demonstrate the clinical use of cardiac magnetic resonance and endomyocardial biopsy in the diagnosis and subsequent monitoring of ICI-associated myocarditis, suggesting ...
Grigorios Chatzantonis, MD, Georg Evers, MD, Claudia Meier, MD, Michael Bietenbeck, PhD, Anca Florian, MD, Karin Klingel, MD, Annalen Bleckmann, MD, Ali Yilmaz, MD   +7 more
doaj   +1 more source

Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review

Frontiers in Oncology, 2023
Immune checkpoint inhibitors cause rare but potentially fatal neuromuscular complications, leading to a concern to use these agents in cancer patients with pre-existing autoimmune or inflammatory neuromuscular diseases.
Ge Xiong, Richard Benjamin Young, Helen Chow, Emanual Maverakis, Ricardo A. Maselli, David Paul Richman, Tianhong Li   +6 more
doaj   +1 more source